Enanta Pharmaceuticals Inc. [ENTA] Sees 6,000 Share Insider Sell From Treasurer, CFO Mellett Paul J
On Jan. 08, Mellett Paul J divested U.S. $273,463 in shares of Enanta Pharmaceuticals Inc.. The Treasurer, CFO sold 6,000 shares at a price per share of $45.58. The transaction decreased this specific insider’s holdings to 61,759 shares worth around $2.82 million at present. Evercore ISI launched its Enanta Pharmaceuticals Inc. [ENTA] rating to the […]
HC Wainwright & Co. maintains Collegium Pharmaceutical [COLL] at Buy rating with a $33 price target
HC Wainwright & Co. maintained its Collegium Pharmaceutical [COLL] rating to the equivalent of Buy but changed the price target to $33.0 from $29, in a research note dated 2021-01-11. That figure represents around a 52.14% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with Guggenheim’s analysts […]
Insider Selling: Varonis Systems Inc. [VRNS] EVP Engineering, CTO Sells 5,500 Shares Worth $937,046
On Jan. 07, Bass David divested U.S. $937,046 in shares of Varonis Systems Inc.. The EVP Engineering, CTO sold 5,500 shares at a price per share of $170.37. The transaction decreased this specific insider’s holdings to 163,775 shares worth around $28.4 million at present. Barclays took its Varonis Systems Inc. [VRNS] rating to the equivalent […]
Chimerix [CMRX] Unchanged to Buy at HC Wainwright & Co.
HC Wainwright & Co. maintained its Chimerix [CMRX] rating to the equivalent of Buy but changed the price target to $16.0 from $7, in a research note dated 2021-01-11. That figure represents around a 90.02% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with H.C. Wainwright’s analysts […]
International Money Express Inc. [IMXI] Insider Just Sold 48,900 Shares. Should You?
On Jan. 06, Lisy Robert divested U.S. $789,303 in shares of International Money Express Inc.. The CEO, Pres, COB sold 48,900 shares at a price per share of $16.14. The transaction decreased this specific insider’s holdings to 1,252,160 shares worth around $20.07 million at present. JMP Securities took its International Money Express Inc. [IMXI] rating […]
HC Wainwright & Co. maintains BridgeBio Pharma [BBIO] at Buy rating with a $87 price target
HC Wainwright & Co. maintained its BridgeBio Pharma [BBIO] rating to the equivalent of Buy but changed the price target to $87.0 from $64, in a research note dated 2021-01-11. That figure represents around a 32.8% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with BofA/Merrill’s analysts […]
Baker Brian Lee Has Sold $3,819,090 in Turning Point Therapeutics Inc. [TPTX] Stock
On Jan. 07, Baker Brian Lee divested U.S. $3,819,090 in shares of Turning Point Therapeutics Inc.. The SVP of Finance, Admin. sold 31,238 shares at a price per share of $122.26. The transaction decreased this specific insider’s holdings to 1,008 shares worth around $0.13 million at present. JMP Securities launched its Turning Point Therapeutics Inc. […]
Applied DNA Sciences [APDN] Unchanged to Buy at HC Wainwright & Co.
HC Wainwright & Co. maintained its Applied DNA Sciences [APDN] rating to the equivalent of Buy but changed the price target to $18.0, in a research note dated 2021-01-11. That figure represents around a 54.64% premium from where the company’s shares closed on Friday. Other analysts also revised their coverage, with H.C. Wainwright’s analysts reiterating […]
Insider Selling Report: Applied Therapeutics Inc. [APLT]’s Chief Medical Officer, Perfetti Riccardo, Sells 16,515 Shares
On Jan. 06, Perfetti Riccardo divested U.S. $383,711 in shares of Applied Therapeutics Inc.. The Chief Medical Officer sold 16,515 shares at a price per share of $23.23. The transaction decreased this specific insider’s holdings to 0 shares worth around $0.0 at present. Truist launched its Applied Therapeutics Inc. [APLT] rating to the equivalent of […]
Andersons [ANDE] gets a downgrade to Market Perform from BMO Capital
BMO Capital took its Andersons [ANDE] rating to the equivalent of Market Perform from Outperform, and the price target to $26.0 from $24, in a research note dated 2021-01-11. That figure represents around a 3.26% premium from where the company’s shares closed on Friday. Other analysts also revised their coverage, with BMO Capital Markets’s analysts […]
